DCAF1 and melanoma: Consistent with the melanoma-promoting effects of VprBP-mediated H2AT120p, treating G361 melanoma xenograft with VprBP inhibitor B32B3 at doses of 2.5 mg/kg or higher over a period of 24 days also markedly increased target gene mRNA levels (Figure 6D and Figure 7D).